Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women

被引：44

作者：

Agorastos, T ^{[1
]}

Vaitsi, V ^{[1
]}

Pantazis, K ^{[1
]}

Efstathiadis, E ^{[1
]}

Vavilis, D ^{[1
]}

Bontis, JN ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippokratio Gen Hosp, Dept Obstet & Gynecol, Thessaloniki 55132, Greece

来源：

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2005年 / 118卷 / 02期

关键词：

anastrozole; endometrial hyperplasia; obesity; menopause;

D O I：

10.1016/j.ejogrb.2004.07.002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

This is a preliminary study investigating the efficacy of aromatase inhibitor anastrozole in treating endometrial hyperplasia in obese postmenopausal women. We administered anastrozole for 12 months to 11 obese postmenopausal women with high operative risk, in order to treat endometrial hyperplasia (four simple, five complex and two atypical). Endometrial thickness in all cases and histology too in the two cases with atypia, revealed atrophical endometrium during treatment and additional mean follow-up of 10.2 months. The safety and tolerance profile was satisfactory. Anastrozole appears to be an interesting new modality for the treatment of endometrial hyperplasia in obese postmenopausal women. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：239 / 240

页数：2